Liraglutide, marketed under the brand names Victoza for diabetes management and Saxenda for weight management, is a versatile GLP-1 receptor agonist with a distinct focus on weight loss
New research from Simple Online Healthcare suggests oral treatments will significantly expand access to obesity care: 61% of people not currently using GLP-1 medications say they would prefer a daily pill Nearly half of existing GLP-1 users prefer a pill format However, existing patients remain focused on effectiveness 88% saying they would only switch if tablets deliver equal or higher results
Demir AN et al
Thornberry grew up in South Bend, Indiana and did a BSc in Natural Sciences at Muhlenberg College in Allentown, Pennsylvania, She joined Merck Research Laboratories as a biochemist in 1979 and became the director of enzymology in 1990
It reduces blemishes, spots, and pigmentation on the skin, leaving it softer, smoother, and glowing in complexion